Vaccinex (VCNX) AI Stock Analysis

• Market Cap: $3.03M
• Dividend Yield: N/A
• Average Volume (3M): 1.22K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.61
• Revenue Growth: 5.44%
• EPS Growth: 84.28%
• Country: US
• Employees: 23
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 2,676,637
• 10 Day Avg. Volume: 776
• 30 Day Avg. Volume: 1,224
• PEG Ratio: <0.01
• Price to Book (P/B): -0.83
• Price to Sales (P/S): 3.42
• P/FCF Ratio: -0.13
• Enterprise Value/Market Cap: 0.32
• Enterprise Value/Revenue: 1.62
• Enterprise Value/Gross Profit: 1.70
• Enterprise Value/Ebitda: -0.05
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: $1.00 ▲(44.93% Upside)

The score is primarily held down by very weak financial fundamentals (losses, negative equity, and cash burn). Technical signals are constructive and provide partial support, but valuation is constrained by negative earnings and no dividend data.

Positive Factors

Proprietary monoclonal antibody platform

Owning a proprietary monoclonal antibody platform and a lead clinical asset (VAC-1) provides durable R&D leverage. A validated platform can enable pipeline expansion, attract partnerships or licensing, and create long-term value if clinical progress continues.

Diverse non-dilutive funding channels

Access to grants, partnerships, milestone payments and future royalties reduces sole dependence on equity raises. Persistent non-dilutive and partnership funding enhances runway and supports sustained development spending without immediate shareholder dilution.

Positive revenue trend

A year-over-year revenue increase, even modest, signals improving commercial or collaboration traction. For a biotech, reproducible revenue growth from grants or partnerships suggests operational progress and a foundation for scaling funding sources over the medium term.

Negative Factors

Negative stockholders' equity

Negative equity is a structural solvency concern that limits borrowing capacity and increases refinancing risk. It can force dilutive capital raises, constrain strategic flexibility, and deter potential partners or acquirers unless corrected by sustained profit or recapitalization.

Persistent cash burn and reliance on financing

Ongoing negative operating and free cash flow implies the company requires external financing to fund operations. Reliance on financing inflows creates execution risk if markets tighten, and increases probability of dilution or unfavorable financing terms over the medium term.

Sustained negative profitability

Prolonged negative net income and poor EBIT margins undermine internal capital generation and long-term viability without external funding. Continued unprofitability can restrict R&D investment, hamper ability to scale, and elevate investor scrutiny over strategy execution.

Vaccinex Business Overview & Revenue Model

Company Description

Vaccinex, Inc. (VCNX) is a biotechnology company focused on developing targeted therapeutics for the treatment of cancer and neurodegenerative diseases. The company specializes in monoclonal antibody technology and has several proprietary product candidates, including its lead drug candidate, VAC-1, which is designed to treat various solid tumors. Vaccinex operates primarily in the healthcare sector, seeking to address unmet medical needs through innovative treatments and therapies.

How the Company Makes Money

Vaccinex generates revenue through multiple channels, primarily focused on the development and commercialization of its therapeutic products. The company earns money through grant funding, partnerships, and collaborations with larger pharmaceutical companies that provide funding in exchange for access to its drug candidates or technology. Additionally, Vaccinex may receive milestone payments based on the progress of its clinical trials and regulatory approvals, as well as potential royalties from future sales of its products. Strategic partnerships with research institutions and other biotech firms also play a crucial role in enhancing its revenue potential.

Vaccinex Financial Statement Overview

Summary

Vaccinex is in a challenging financial position with sustained losses, negative equity, and poor cash flow. Despite slight revenue growth, the financial instability and reliance on external financing present significant risks.

Income Statement

The company shows poor profitability with persistent negative net income and EBIT margins. Although there was a slight increase in revenue from 2023 to 2024, the company is still operating at a loss. The revenue growth rate is positive, but the overall trend of high expenses and significant losses overshadows this growth.

Balance Sheet

The company's balance sheet is weak, characterized by negative stockholders' equity, indicating liabilities exceed assets. The debt-to-equity ratio cannot be calculated due to negative equity, and the equity ratio is negative, highlighting financial instability and potential risk.

Cash Flow

Cash flow statements show negative operating and free cash flow, indicating the company is burning cash. However, financing cash flows have been positive, providing some liquidity relief. The free cash flow to net income ratio is not improving significantly, reflecting ongoing cash flow challenges.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	601.00K	570.00K	100.00K	900.00K	50.00K
Gross Profit	601.00K	570.00K	68.00K	731.00K	48.00K
EBITDA	-18.54M	-19.75M	-19.61M	-21.40M	-28.05M
Net Income	-18.63M	-20.25M	-19.72M	-22.38M	-28.85M
Balance Sheet
Total Assets	2.60M	3.63M	7.98M	9.84M	11.70M
Cash, Cash Equivalents and Short-Term Investments	1.11M	1.53M	6.39M	8.59M	10.60M
Total Debt	25.00K	247.00K	485.00K	390.00K	9.21M
Total Liabilities	5.08M	5.94M	2.78M	2.43M	14.31M
Stockholders Equity	-2.49M	-2.31M	5.19M	7.41M	-26.57M
Cash Flow
Free Cash Flow	-16.21M	-17.30M	-19.17M	-25.33M	-28.94M
Operating Cash Flow	-16.19M	-17.23M	-19.07M	-25.30M	-28.65M
Investing Cash Flow	-22.00K	-67.00K	-99.00K	-32.00K	-290.00K
Financing Cash Flow	15.78M	12.45M	16.98M	23.32M	36.76M

Vaccinex Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.69
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VCNX, the sentiment is Positive. The current price of 0.69 is below the 20-day moving average (MA) of 0.98, below the 50-day MA of 0.76, and below the 200-day MA of 0.74, indicating a bullish trend. The MACD of 0.11 indicates Negative momentum. The RSI at 64.16 is Neutral, neither overbought nor oversold. The STOCH value of 56.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VCNX.

Vaccinex Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
VCNX	47 Neutral	$3.03M	-0.12	1406.28%	―	5.44%	84.28%
GTBP	47 Neutral	$7.02M	-0.22	-356.99%	―	―	54.62%
TOVX	45 Neutral	$7.16M	-0.04	-166.96%	―	―	83.25%
AZTR	45 Neutral	$2.96M	-0.06	-215.04%	―	-100.00%	93.82%
REVB	43 Neutral	$5.33M	-0.03	-118.88%	―	―	96.26%